Immune Design Corp., a Seattle, WA-based biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, has secured $32m in Series B financing.
The investment was led by ProQuest Investments, with participation from existing investors The Column Group, Versant Ventures, and Alta Partners.
This latest round brings the total amount of equity capital raised by Immune Design to $50m since its inception in 2008.
In conjunction with the financing, ProQuest general partner, Alain Schreiber, M.D., will join the company’s board.
The funds will be used to accelerate Immune Design’s lead candidates through clinical studies and further expanding development of new vaccines and therapeutics.
It is currently advancing an innovative vaccine pipeline utilizing its two proprietary technologies which include:
– GLA, a novel, synthetic, toll-like receptor 4 (TLR-4) agonist, which is a clinical stage adjuvant being developed as a component in multiple internal and partnered vaccine programs;
– DC-NILV, a novel delivery vector engineered to target human dendritic cells and express target antigens and immunomodulatory elements to elicit functional and broad based immunity, which is initially being applied in cancer indications of significant unmet need.